Improved vocal quality and decreased vocal effort after botulinum toxin treatment for laryngeal dystonia.

Auris, nasus, larynx 2024 Vol.51(1) p. 106-112

Leung JS, Rosenbaum A, Holmberg J, Villarroel P, Napolitano C, Badía PI, Lagos-Villaseca A

관련 도메인

Abstract

[OBJECTIVES] Laryngeal dystonia (LD) is characterized by irregular and involuntary task-specific spasms of the intrinsic laryngeal muscles. There is no curative treatment for it, however, laryngeal botulinum neurotoxin injections (BoNT-I) are considered the standard of care therapy. This study aims to characterize the population of LD patients and to assess the results of laryngeal BoNT-I.

[METHODS] A Retrospective cohort study was conducted. Medical records were reviewed for all the patients with LD diagnosis seen in the Voice Unit of the Red de Salud UCChristus between January 2013 and October 2021. Biodemographic, clinical and treatment data were collected. Additionally, a telephonic survey was completed by the patients that underwent laryngeal BoNT-I, including self-reported voice outcomes and Voice Handicap Index 10 (VHI-10).

[RESULTS] Of the 34 patients with LD included in the study, 23 received a total of 93 laryngeal BoNT-I and 19 completed the telephone survey. The majority (97%) of the injections corresponded to patients with adductor LD and 3% to abductor LD. Patients received a median of 3 (1-17) injections, with a more frequent cricothyroid approach (94.4%), while the thyrohyoid approach accounted for 5.6% of cases. Most injections were bilateral (96.8%). A significant improvement in the vocal quality and effort was noted after the last injection and the overall BoNT-I treatment (P < 0.001). Similarly, the VHI-10 score improved from a median of 31 (7-40) to 2 (0-19) (P < 0.001) after the last injection. A post-treatment breathy voice was reported in 95% of patients, and dysphagia to liquids and solids in 68% and 21%, respectively.

[CONCLUSIONS] Laryngeal BoNT-I is an effective treatment for LD, achieving an improvement in self-reported vocal quality and VHI-10 scores, and a reduction of the self-reported vocal effort. Adverse effects are mild in the majority of cases, constituting a safe and effective therapy for these patients.

추출된 의학 개체 (NER)

유형영어 표현한국어 / 풀이UMLS CUI출처등장
시술 botulinum toxin 보툴리눔독소 주사 dict 1
해부 laryngeal scispacy 1
해부 laryngeal muscles scispacy 1
해부 thyrohyoid scispacy 1
합병증 laryngeal BoNT-I. scispacy 1
합병증 laryngeal scispacy 1
약물 solids C0205208
Solid
scispacy 1
약물 [OBJECTIVES] Laryngeal dystonia scispacy 1
약물 Red scispacy 1
약물 [CONCLUSIONS] Laryngeal BoNT-I scispacy 1
질환 laryngeal dystonia C1963946
Laryngeal dystonia
scispacy 1
질환 involuntary task-specific spasms scispacy 1
질환 dysphagia C0011168
Deglutition Disorders
scispacy 1
질환 laryngeal BoNT-I scispacy 1
질환 adductor LD scispacy 1
질환 abductor LD scispacy 1
기타 laryngeal botulinum neurotoxin scispacy 1
기타 patients scispacy 1
기타 cricothyroid scispacy 1

MeSH Terms

Humans; Botulinum Toxins; Dystonia; Retrospective Studies; Dysphonia; Voice Quality; Laryngeal Muscles; Treatment Outcome; Botulinum Toxins, Type A

🔗 함께 등장하는 도메인

이 논문이 속한 카테고리와 같은 논문에서 자주 함께 다뤄지는 카테고리들

관련 논문